Trial Number

129-20

Condition

Lymphoma

Participant Age Range

18 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

“A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)”

This study will compare the efficacy and safety in of LOXO-305 administered as a continuous monotherapy with Investigator’s choice of standard of care IdelaR or BR. The patient population will have received prior BTK inhibitor therapy as part of any number of prior therapies. Therefore, the patient population is heterogeneous in regards to treatment exposure and future prognosis.

Provider

Cancer Institute

Amol H. Rao, MD

Hematology-Oncology, Internal Medicine
Fountain Valley, Laguna Hills
View Profile

Locations

Long Beach Medical Center

2801 Atlantic Avenue
Long Beach
(562) 933-2000
Location Details

Orange Coast Medical Center

18111 Brookhurst Street
Fountain Valley
(714) 378-7000
Location Details

Saddleback Medical Center

24451 Health Center Drive
Laguna Hills
(949) 837-4500
Location Details

Related Clinical Trials

Click on the category you are interested in.

Cancer Care Long Beach Medical Center Orange Coast Medical Center Saddleback Medical Center
Name
Address
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.